Information  X 
Enter a valid email address

PureTech Health PLC (PRTC)

  Print      Mail a friend

Tuesday 09 May, 2017

PureTech Health PLC

Annual Capital Markets Meeting

RNS Number : 5318E
PureTech Health PLC
09 May 2017
 

 

 

PureTech Health Annual Capital Markets Meeting, London

 

Annual Capital Markets Meeting

 

PureTech Health plc ("PureTech Health" or the "Company", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is today holding its second annual Capital Markets Meeting in London. The Company will provide insight into its near-term commercialisation and monetisation strategy as well as insights into its growing research and development pipeline.

 

The meeting will take place in London from 13.00-17.00 BST and will feature PureTech Health presenters including members of the Company's Board of Directors and key scientific advisors. 

 

Speaker

Topic

Chris Viehbacher

Independent Non-Executive Director, PureTech Health; Managing Partner at Gurnet Point Capital and Former CEO of Sanofi

Welcome: Perspectives on PureTech Health's unique place in biopharma ecosystem

Daphne Zohar

Co-Founder & Chief Executive Officer, PureTech Health

Building a modern biopharma company

Near-Term Catalysts

LeRoux Jooste

Chief Commercial Officer, Akili Interactive; Former CCO/SVP of Business Development at Ocata (Astellas)

Akili Interactive: Imagine what medicine can be

Eddie Martucci, Ph.D.

Vice President, PureTech Health; Co-Founder and Chief Executive Officer, Akili Interactive 

Raju Kucherlapati, Ph.D.

Independent Non-Executive Director and Scientific Advisory Board Member, PureTech Health; Co-founder of Millennium Pharmaceuticals and Abgenix

Transitioning from a clinical to commercial-stage biopharma company

Eric Elenko, Ph.D.

Chief of Research and Strategy, PureTech Health

Gelesis: Targeting the genesis of chronic disease

Follica: Resetting the clock on skin biology

John LaMattina, Ph.D.

Independent Non-Executive Director, PureTech Health; Former President of Global Research and Development at Pfizer

Developing new classes of medicine

Bernat Olle, Ph.D.

Vice President, PureTech Health; Co-Founder and Chief Executive Officer, Vedanta Biosciences 

Vedanta Biosciences: Microbiome-derived immunotherapies

Partnering with Big Pharma to Advance Important New Medicines

Bennett Shapiro, M.D.

Co-Founder & Non-Executive Director, PureTech Health; Former Executive Vice President of Research at Merck

Partnering with big pharma to advance important new medicines

Andrew Miller, Ph.D.

Vice President, PureTech Health; Co-Founder and Chief Executive Officer, Karuna Pharmaceuticals

Karuna Pharmaceuticals: Treating cognition and psychosis associated with neurological disease

Chen Schor

Senior Executive, PureTech Health; Co-Founder and Chief Executive Officer, resTORbio

resTORbio: Aging and the immune system

A Growing Immunology Pipeline and the Next Wave of Innovation

Joe Bolen, Ph.D.

Chief Scientific Officer, PureTech Health; Former President and CSO of Moderna and former CSO of Millennium (Takeda)

The adaptive human systems and a growing immunology pipeline

Aleks Radovic-Moreno, Ph.D.

Senior Associate, PureTech Health; Co-Founder of Commense, Alivio, and Vor; Formerly MIT

Commense: Developing microbiome-derived interventions for maternal and paediatric health

 

Alivio: Treating chronic and acute inflammatory disorders

 

Vor: Developing next-generation engineered cell therapies in oncology

Aleks Filipovic, M.D., Ph.D.

Therapeutic Lead for Oncology, PureTech Health; Co-Founder of Nybo; Formerly Imperial College

Nybo: Developing monoclonal antibodies to target pancreatic cancer and other solid tumours

Grace Teo, Ph.D.
Associate, PureTech Health; Co-Founder of Nybo; Formerly MIT

Concept stage programmes: The next wave of innovation

David Steinberg

Chief Innovation Officer, PureTech Health

Translating innovation into medicine

Atul Pande, M.D.

Chief Medical Officer, PureTech Health;

Former Senior Vice President and Head of Neuroscience at GSK

Bharatt Chowrira, Ph.D., J.D.

President and Chief of Business and Strategy, PureTech Health; Former President of Synlogic and COO of Auspex (Teva)

Unlocking value

Marjorie Scardino

Senior Independent Director, PureTech Health;

Former CEO of Pearson plc and The Economist

Closing remarks

 

If you would like to attend the event, please contact  [email protected] 

 

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines that modulate the adaptive human systems. PureTech's therapies target the dysfunctions in the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. The Company is advancing a rich pipeline that includes multiple human proof-of-concept studies and pivotal or registration studies expected to read out over the next 12-18 months. PureTech Health's growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts, who along with PureTech's experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information:


PureTech Health

FTI Consulting

 

Allison Mead

+1 617 651 3156

[email protected]

Ben Atwell, Matthew Cole, Rob Winder

+44 (0) 20 3727 1000

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAASPEFFXEAF

a d v e r t i s e m e n t